- Thermodynamic characteristics of protolytic equilibria in aqueous solutions of glycyl peptides
-
Protolytic equilibria in aqueous solutions of glycyl-DL-serine, glycyl-DL-threonine, and glycyl-DL-valine are investigated by means of potentiometry and calorimetry. Dissociation constants and heat effects of the above dipeptides are determined. Standard
- Gridchin
-
p. 2170 - 2176
(2016/10/24)
-
- THERAPEUTIC AGENT FOR PRURITUS
-
The present inventors isolated clone BM095 from a human antibody phage library, which had a strong growth inhibitory activity in the IL-31-dependent Ba/F3 cell growth assay system. When administered to pruritus model mice, the anti-mouse NR10 neutralizing antibody exhibited a marked symptom-suppressing effect. Thus, it was revealed that anti-NR10 neutralizing antibodies are useful as therapeutic agents for pruritus.
- -
-
-
- Disulfide bridged cyclic peptides containing a cgridri sequence useful in control of hypertension
-
Disulfide bridged cyclic peptides are described which are preferably 13 to 20 amino acid residues in length and which include the endocyclic sequence cys-gly-arg-ile-asp-arg-ile. Peptides of this class are selective for and show picomolar-range affinity for the non-guanyl cyclase-coupled atrial peptide receptor. Affinity for this receptor is associated with potentiation of the mean arterial pressure response to atrial peptide and these peptides are therefore useful in control of hypertension. Peptides of most interest are of the formula wherein X1 is the peptidic fragment ser-ser; wherein X2 is a peptidic fragment selected from gly-ser-gly-leu, gly-ala-gly-leu and gly-leu; wherein X3 is the peptidic fragment asn-ser-phe-arg; wherein m is zero or one, n is one and r is one; and wherein A represents an amino terminus or its pharmaceutically--acceptable salt, and B represents a carboxyl terminus or its pharmaceutically-acceptable ester, amide or salt.
- -
-
-
- Pharmaceutical preparations having diuretic activity
-
Pharmaceutical preparations having diuretic activity and comprising a peptide of the formula STR1 wherein (a) R1 and R2 are hydrogen and R3 is --OH, or STR2 or Y, or wherein (b) R1 is hydrogen, R2 is CH2 OH or STR3 and R3 is --OH or Y, or wherein (c) R1 is --CH2 OH and R2 is hydrogen or STR4 and R3 is --OH or Y, or wherein (d) R1 is STR5 R2 is hydrogen or --CH2 OH and R3 is --OH, --NHCH2 COOH, or Y, and wherein X is hydrogen, methyl, prolyl, or an N-protective group, and Y is --NH2, --OR4, wherein R4 is linear or branched alkyl or cyclolalkyl having from 1 to 8 carbon atoms, benzyl, phenyl, or STR6
- -
-
-
